Recent Developments on Future Antidepressant-related Serotonin Receptors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Amidfar, Meysam | - |
dc.contributor.author | Kim, Yong-Ku | - |
dc.date.accessioned | 2021-09-02T21:12:23Z | - |
dc.date.available | 2021-09-02T21:12:23Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 1381-6128 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/80924 | - |
dc.description.abstract | Conventional serotonin-enhancing antidepressants including selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) have shown effectiveness in the treatment of major depression, but their significant limitations such as slowness of action have led to intensive research efforts to develop new antidepressants. Increased synaptic neurotransmission of serotonin (5-hdroxytryptamine; 5-HT) through orchestration of stimulation and blockade of various subtypes of 5-HT receptors is involved in the mechanisms of action of SSRIs. Agonists at the 5-HT1A, 5-HT1B, 5-HT2C, 5-HT4, and 5-HT6 receptors and antagonists at the 5-HT1A, 5-HT2A, 5-HT2C, 5-HT3, 5-HT6, and 5-HT7 receptors have shown antidepressant properties in clinical and preclinical studies. However, paradoxical antidepressant-like effects of both agonists and antagonists at particular 5-HT receptors suggest the need to consider the neurochemical mechanisms of each 5-HT receptor subtype. Therefore, better knowledge of the involvement of individual 5-HT receptors in the mechanisms of action of currently used antidepressants as well as antidepressant effects of selective ligands of 5-HT receptor subtypes will provide opportunities for the development of future antidepressants with more rapid onset of action, fewer side effects, and better efficacy than SSRIs. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | BENTHAM SCIENCE PUBL LTD | - |
dc.subject | MAJOR DEPRESSIVE DISORDER | - |
dc.subject | PLACEBO-CONTROLLED TRIAL | - |
dc.subject | FORCED SWIMMING TEST | - |
dc.subject | ANTI-IMMOBILITY ACTION | - |
dc.subject | EYE-MOVEMENT SLEEP | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | 5-HT3 RECEPTOR | - |
dc.subject | PINDOLOL AUGMENTATION | - |
dc.subject | REUPTAKE INHIBITORS | - |
dc.subject | IN-VIVO | - |
dc.title | Recent Developments on Future Antidepressant-related Serotonin Receptors | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yong-Ku | - |
dc.identifier.doi | 10.2174/1381612824666180803111240 | - |
dc.identifier.scopusid | 2-s2.0-85055497166 | - |
dc.identifier.wosid | 000447761000005 | - |
dc.identifier.bibliographicCitation | CURRENT PHARMACEUTICAL DESIGN, v.24, no.22, pp.2541 - 2548 | - |
dc.relation.isPartOf | CURRENT PHARMACEUTICAL DESIGN | - |
dc.citation.title | CURRENT PHARMACEUTICAL DESIGN | - |
dc.citation.volume | 24 | - |
dc.citation.number | 22 | - |
dc.citation.startPage | 2541 | - |
dc.citation.endPage | 2548 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | MAJOR DEPRESSIVE DISORDER | - |
dc.subject.keywordPlus | PLACEBO-CONTROLLED TRIAL | - |
dc.subject.keywordPlus | FORCED SWIMMING TEST | - |
dc.subject.keywordPlus | ANTI-IMMOBILITY ACTION | - |
dc.subject.keywordPlus | EYE-MOVEMENT SLEEP | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | 5-HT3 RECEPTOR | - |
dc.subject.keywordPlus | PINDOLOL AUGMENTATION | - |
dc.subject.keywordPlus | REUPTAKE INHIBITORS | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordAuthor | Serotonin | - |
dc.subject.keywordAuthor | antidepressant | - |
dc.subject.keywordAuthor | depression | - |
dc.subject.keywordAuthor | SSRI | - |
dc.subject.keywordAuthor | synaptic neurotransmission of serotonin | - |
dc.subject.keywordAuthor | selective serotonin reuptake inhibitors | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.